Manabu Hayata Selected Research

camostat

8/2021	A serine protease inhibitor camostat mesilate prevents podocyte apoptosis and attenuates podocyte injury in metabolic syndrome model rats.
10/2016	A serine protease inhibitor attenuates aldosterone-induced kidney injuries via the suppression of plasmin activity.
2/2016	Combination therapy with renin-angiotensin-aldosterone system inhibitor telmisartan and serine protease inhibitor camostat mesilate provides further renoprotection in a rat chronic kidney disease model.
1/2015	The serine protease inhibitor camostat mesilate attenuates the progression of chronic kidney disease through its antioxidant effects.
7/2013	The antifibrotic effect of a serine protease inhibitor in the kidney.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Manabu Hayata Research Topics

Disease

5	Fibrosis (Cirrhosis) 10/2016 - 10/2012
3	Proteinuria 08/2021 - 10/2012
3	Chronic Renal Insufficiency 02/2016 - 01/2015
2	Wounds and Injuries (Trauma) 08/2021 - 10/2016
2	Hypertension (High Blood Pressure) 08/2021 - 10/2012
2	Albuminuria 11/2020 - 01/2016
2	Ureteral Obstruction 10/2016 - 07/2013
1	Acute Kidney Injury (Acute Renal Failure) 01/2022
1	Reperfusion Injury 01/2022
1	Ischemia 01/2022
1	Rodent Diseases 08/2021
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 08/2021
1	Disease Progression 11/2020
1	Premature Aging 01/2020
1	Kidney Diseases (Kidney Disease) 10/2016
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2016
1	Lupus Nephritis 03/2015
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 03/2015
1	Nephritis 03/2015
1	Focal Segmental Glomerulosclerosis (Glomerulosclerosis, Focal) 03/2015
1	Insulin Resistance 03/2014
1	Chronic Kidney Failure (Chronic Renal Failure) 10/2012
1	Hypertrophy 10/2012

Drug/Important Bio-Agent (IBA)

7	Serine Proteinase Inhibitors (Serine Protease Inhibitors)IBA 08/2021 - 10/2012
5	camostatIBA 08/2021 - 07/2013
3	CreatinineIBA 01/2022 - 10/2012
3	Serine Proteases (Serine Protease)IBA 08/2021 - 03/2014
2	nephrinIBA 11/2020 - 10/2012
2	SaltsIBA 10/2016 - 10/2012
2	Adenine FDA LinkGeneric 02/2016 - 01/2015
2	Proteins (Proteins, Gene)FDA Link 01/2015 - 10/2012
2	CollagenIBA 07/2013 - 10/2012
1	Adenosine Triphosphate (ATP)IBA 01/2022
1	KUS121IBA 01/2022
1	Valosin Containing ProteinIBA 01/2022
1	Lipocalin-2IBA 01/2022
1	RNA (Ribonucleic Acid)IBA 11/2020
1	AldosteroneIBA 10/2016
1	Fibrinolysin FDA Link 10/2016
1	Telmisartan (Micardis)FDA Link 02/2016
1	Prednisolone (Predate)FDA LinkGeneric 03/2015
1	Methylprednisolone FDA LinkGeneric 03/2015
1	LDL Lipoproteins (beta Lipoproteins)IBA 03/2015
1	LDL CholesterolIBA 03/2015
1	oxidized low density lipoproteinIBA 03/2015
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 03/2015
1	CholesterolIBA 03/2015
1	Messenger RNA (mRNA)IBA 01/2015
1	AntioxidantsIBA 01/2015
1	NADPH Oxidases (NAD(P)H oxidase)IBA 01/2015
1	Toll-Like Receptor 4IBA 03/2014
1	prostasinIBA 03/2014
1	Transforming Growth Factors (Transforming Growth Factor)IBA 07/2013
1	Plasminogen Activators (Plasminogen Activator)IBA 07/2013
1	Hydroxyproline (4 Hydroxyproline)IBA 07/2013
1	Matrix Metalloproteinase 2 (Gelatinase A)IBA 07/2013
1	Connective Tissue Growth FactorIBA 07/2013

Therapy/Procedure

3	Therapeutics 02/2016 - 03/2015
1	Renal Dialysis (Hemodialysis) 01/2020
1	Blood Component Removal (Apheresis) 03/2015
1	Nephrectomy 10/2012